LAVA Therapeutics (NASDAQ:LVTX) Major Shareholder Gilde Healthcare Cooperatieve Sells 28,954 Shares of Stock

LAVA Therapeutics N.V. (NASDAQ:LVTX) major shareholder Gilde Healthcare Cooperatieve sold 28,954 shares of the company’s stock in a transaction that occurred on Wednesday, October 8th. The shares were sold at an average price of $1.57, for a total value of $45,457.78. Following the completion of the sale, the insider owned 5,392,216 shares in the company, valued at approximately $8,465,779.12. This represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Gilde Healthcare Cooperatieve also recently made the following trade(s):

• On Friday, October 10th, Gilde Healthcare Cooperatieve sold 49,869 shares of LAVA Therapeutics stock. The stock was sold at an average price of $1.55, for a total value of $77,296.95.
• On Thursday, October 9th, Gilde Healthcare Cooperatieve sold 48,169 shares of LAVA Therapeutics stock. The stock was sold at an average price of $1.56, for a total value of $75,143.64.

LAVA Therapeutics Price Performance

NASDAQ LVTX opened at $1.55 on Friday. The firm has a market cap of $40.78 million, a PE ratio of -1.48 and a beta of 0.50. LAVA Therapeutics N.V. has a one year low of $0.85 and a one year high of $2.09. The stock’s 50 day simple moving average is $1.55 and its 200 day simple moving average is $1.39.

LAVA Therapeutics (NASDAQ:LVTX) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). As a group, equities analysts expect that LAVA Therapeutics N.V. will post -1.13 earnings per share for the current year.

Analysts Set New Price Targets

LVTX has been the topic of a number of research analyst reports. HC Wainwright decreased their price target on LAVA Therapeutics from $1.50 to $1.24 and set a “neutral” rating on the stock in a research report on Tuesday, August 5th. Jefferies Financial Group downgraded LAVA Therapeutics from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $3.00 to $1.50 in a report on Tuesday, August 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LAVA Therapeutics in a report on Wednesday. Six analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Reduce” and a consensus target price of $2.69.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in LVTX. Lepercq De Neuflize Asset Management LLC acquired a new position in shares of LAVA Therapeutics in the 1st quarter valued at $29,000. XTX Topco Ltd acquired a new position in shares of LAVA Therapeutics in the 1st quarter valued at $31,000. Rangeley Capital LLC acquired a new position in shares of LAVA Therapeutics in the 2nd quarter valued at $36,000. Finally, BML Capital Management LLC acquired a new position in shares of LAVA Therapeutics in the 1st quarter valued at $2,490,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.